echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Clinical trials of Prueline for COVID-19 completed the group of 381 subjects

    Clinical trials of Prueline for COVID-19 completed the group of 381 subjects

    • Last Update: 2020-11-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    NCT04446429 is a double-blind and placebo-controlled clinical trial designed to explore the role of anti-androgen drugs in fighting new coronavirus infections.
    the clinical trial included non-hospitalized male subjects over the age of 50 with androgenic hair loss, all of who had mild or moderate COVID-19.
    the study used evythromycin and azithromycin as a standard treatment.
    trials were set up in three groups, including the trial group that received "dotamphetamine plus standard treatment", the trial group that received "pruamine plus standard treatment" and the control group that received "placebo plus standard treatment".
    the end of the clinical trial included the percentage of subjects hospitalized for COVID-19, the time of remission, and the severity of symptoms, including 26 clinical symptoms, from mild fever to loss of smell.
    note: There are deletions in the original text
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.